Myeloma Patients Europe (MPE) is participating in the Horizon 2020 project, MMPredict, aimed at developing a personalised medicine tool to predict the most effective treatment strategy for individual myeloma patients.
The MMpredict consortium has reached a new milestone in this project by completing the recruitment of the patient samples required in this project. With more than 800 myeloma samples recruited, the project team meets its aimed target population. The current efforts will now be focused on completing the genetic analysis of the obtained study material. During this stage, tumour heterogeneity (i.e. the differences between people’s myeloma) and the patient’s intrinsic characteristics will be investigated.
By analysing the samples gathered, the consortium aims to explore correlations between the genetic characteristics of the samples, treatment responses and side-effects. In the longer term, these results could help doctors to choose the best treatment for each individual patient and reduce side-effects while improving treatment efficacy. Ultimately, the final goal of the MMPredict project is to develop a tool that predicts the most effective treatment strategy for each individual myeloma patient, thereby improving health outcomes, preventing side-effects and reducing healthcare costs.
To include the patient perspective in MMPredict, MPE ran a survey for European myeloma patients to understand their quality of life and how this is impacted by treatment side-effects. More than 400 patients across Europe participated in this survey which results are currently being analysed. The project consortium would like to thank MPE members for supporting this survey and every patient that took the time to participate.
The main goals of MMPredict are explained in the video below, filmed with some partners working in the project consortium. This video was recorded in English and has been translated into four additional languages: German, Spanish, Dutch and Italian: